BCL11A enhancer modified autologous hematopoietic stem cells (Edigene)

CRISPR/Cas9 基因修饰BCL11A红系增强子的自体CD34+造血干祖细胞（广州辑因医疗科技）

Report date: 2024/10/23 15:58:08

Base Information

Drug NameBCL11A enhancer modified autologous hematopoietic stem cells (Edigene)
Drug Alias NameET-01 (Edigene)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionStem cell replacementsBCL11A gene inhibitors
TargetsB-cell lymphoma/leukemia 11A
Therapy Area/Indicationsbeta-Thalassemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEdigene Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesEdigene Inc
Inactive CompaniesEdiGene Guangzhou Inc
Active Indicationsbeta-Thalassemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A